UTAH MEDICAL PRODUCTS INC

For the period ended Dec 31, 2024. Filed Mar 26, 2025.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Mar 26, 2025

UTMD$72.86-0.0%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Income and Comprehensive Income

UTAH MEDICAL PRODUCTS, INC.
CONSOLIDATED STATEMENTS OF INCOME
AND COMPREHENSIVE INCOME
Years ended December 31, 2024, 2023 and 2022
(In thousands, except per share amounts)
2024 · 2023 · 2022
Sales, net (notes 1, 3, 9 and 11)		$40,903		$50,224		$52,281
Cost of goods sold		16,760		20,186		20,085
		Gross profit		24,143		30,038		32,196
Operating expense:
	Sales and marketing		1,901		1,685		1,507
	Research and development		813		560		493
	General and administrative		7,835		11,016		10,406
		Operating income		13,594		16,777		19,790
Other income (expense):
	Dividend and interest income		3,367		3,036		661
	Royalty income (note 12)		15		20		20
	Other, net		(174)		256		188
		Income before provision for income taxes		16,802		20,089		20,659
Provision for income taxes (note 7)		2,928		3,454		4,186
		Net income		$13,874		$16,635		$16,473
Earnings per common share (basic) (note 1):		$3.96		$4.58		$4.53
Earnings per common share (diluted) (note 1):		$3.96		$4.57		$4.52
Other comprehensive income (loss):
	Foreign currency translation net of taxes of $0 in all periods		$(1,249)		$1,381		$(2,986)
		Total comprehensive income		$12,625		$18,016		$13,487
See accompanying notes to financial statements.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.